NEW BRUNSWICK (New Jersey) April 16 — Johnson & Johnson reported first-quarter revenue above analysts’ estimates today, driven partly by demand for its Stelara treatment for psoriasis and Crohn’s disease and cancer drugs Darzalex and Imbruvica.
J&J, the first major drugmaker to report first-quarter results, reported a slight rise in quarterly sales to US$20.02 billion (RM82.8 billion), above the average analyst estimate of US$19.61 billion, according to IBES data from Refinitiv.
The US healthcare conglomerate said net profit fell to US$3.75 billion, or US$1.39 per share, from US$4.37 billion, or US$1.60 per share, a year earlier.
J&J recorded litigation expense of US$423 million in the first quarter. The company not record litigation expense in the year-ago period. — Reuters
